Buy vs. Build: The True Cost of a Healthcare Test Data Program
At some point, every engineering leader running healthcare integration or QA asks the same question: should we write our own synthetic test data generator, or should we buy one? It looks like a simple build-vs-buy call — the kind teams make about logging tools or CI runners every quarter. It usually isn't. Test data generation for HL7 v2 and X12 EDI has a shape that makes the "just build it" instinct more expensive than it first appears, and a fair comparison has to say so plainly rather than assume the answer.
Why This Decision Keeps Coming Up
Almost every healthcare IT and integration team eventually needs realistic test data — for go-lives, EHR upgrades, clearinghouse connectivity testing, regression suites, or QA environments — and almost every team's first instinct is to write a script. A generator that emits a plausible-looking HL7 ADT message or an 837 claim is not, on the surface, a hard engineering problem. That's exactly what makes the decision worth slowing down on: the first version is deceptively cheap to build, and the real cost shows up later.
The Part That's Easy to Underestimate
A script that produces one well-formed segment is not the same thing as a test data program. The gap between the two is usually where build estimates go wrong, for a few specific reasons:
None of these is a one-time cost. Each is a recurring obligation that competes with product roadmap work indefinitely, for as long as the tool is in use.
Buy vs. Build, Side by Side
The table below is meant as a directional comparison, not a scored scorecard — the right weight to put on each row depends on your team's size, timeline, and how central test data is to your roadmap.
| Dimension | Build In-House | Buy (e.g. Synthibase) |
|---|---|---|
| Initial cost | Often more than teams initially budget for — a basic generator is quick, but a usable, scenario-coherent one is a multi-sprint project | Predictable subscription cost, working within days rather than sprints |
| Ongoing maintenance | Usually the most underestimated part — implementation guide changes, new payer rules, and new transaction types all require continued engineering attention | Maintenance is the vendor's core product responsibility, not a side task for your team |
| Opportunity cost | Engineering time spent on test-data tooling is time not spent on product-facing work | Engineering stays focused on the product; test data is a line item, not a project |
| Continuity risk | Knowledge concentrates in one or two engineers; turnover can leave the tool unmaintained or poorly understood | Continuity is the vendor's responsibility, independent of any one person on your team |
| Customization | Full control — you can shape the tool exactly to one narrow internal workflow | Less flexible than a purpose-built script; works within the vendor's supported scenarios and configuration options |
| Vendor dependency | None — no external roadmap, pricing, or support relationship to manage | Real tradeoff — you're relying on a third party's roadmap, uptime, and support quality |
When Building Actually Makes Sense
Buying isn't automatically the right call, and a fair comparison should say where build wins. If your need is genuinely narrow — one message type, one payer, one internal workflow that will never expand — a small internal script can be the pragmatic choice, and the maintenance burden stays proportionally small. Building also makes sense when a specific compliance or data-residency requirement mandates that test data generation happen entirely in-house, with no external service in the loop at all. And if your organization already has a team whose job is to own internal developer tooling long-term, the turnover risk that usually undermines DIY generators is mitigated by design. The mistake isn't building — it's building without accounting for what the tool will cost to keep valid and coherent a year or two after the first version ships.
For most healthcare IT and engineering teams, though, the need isn't narrow. It spans multiple transaction types, multiple payers or trading partners, and scenarios that have to stay linked and clinically coherent across a full patient record — which is exactly the part of the problem that's hardest to keep sustainable in-house.
Where Synthibase Fits
Synthibase exists because most teams land on the "buy" side of this comparison once they've actually tried to maintain a generator through a few implementation guide updates and a staffing change. It generates synthetic HL7 v2 and X12 EDI test data from a coherent synthetic patient registry — so a patient's demographics, coverage, providers, and linked transactions stay consistent across an entire scenario, not just valid segment by segment. There's no PHI involved, no in-house parser logic to keep current, and no single engineer whose departure puts your test data pipeline at risk.